RPL-554 (LS-193855) is a drug which acts as a long-acting inhibitor of the phosphodiesterase enzymes PDE-3 and PDE-4 producing both bronchodilator and antiinflammatory effects. It is being developed by Verona Pharma as a potential treatment for asthma and hay fever and is currently in clinical trials.
This page contains content from the copyrighted Wikipedia article "RPL-554"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
